Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 431-438

  Shiragami, Risa ^a   Murata, Soichiro ^a   Kosugi, Chihiro ^a   Tezuka, Tohru ^a   Yamazaki, Masato ^a   Hirano, Atsushi ^a   Yoshimura, Yukino ^a   Suzuki, Masato ^a   Shuto, Kiyohiko ^a   Koda, Keiji ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Cerulenin; Colorectal cancer; Oxaliplatin

Indexed keywords

CASPASE 3; CERULENIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERULENIN; COLONIC NEOPLASMS; FATTY ACID SYNTHASES; FATTY ACID SYNTHESIS INHIBITORS; HCT116 CELLS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS;

EID: 84879668478     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1978     Document Type: Article

References (28)

1. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006. (Pubitemid 44781029)
2. Tachimori A, Yamada N, Amano R, et al: Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28: 629-638, 2008. (Pubitemid 351578902)
3. Kuhajda FP: Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66: 5977-5980, 2006.
4. Elbaz A, Wu X, Rivas D, et al: Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med 14: 982-991, 2010.
5. Wils J: Adjuvant treatment of colon cancer: past, present and future. J Cemother 19: 115-122, 2007.
6. Pires IM, Ward TH and Dive C: Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol 159: 1326-1338, 2010.
7. Ramanathan RK, Clark JW, Kemeny NE, et al: Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 21: 2904-2911, 2003. (Pubitemid 46621840)
8. Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R and Ohkohchi N: Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci 101: 1861-1865, 2010.
9. Orita H, Coulter J, Lemmon C, et al: Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 13: 7139-7145, 2007. (Pubitemid 350276900)
10. Wang HQ, Altomare DA, Skele KL, et al: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574-3582, 2005. (Pubitemid 40756227)
11. Rouse J, Cohen P, Trigon S, et al: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78: 1027-1037, 1994. (Pubitemid 24292330)
12. Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811, 1994. (Pubitemid 24266145)
13. Lee JC, Laydon JT, McDonnell PC, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994.
14. Freshney NW, Rawlinson L, Guesdon F, et al: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78: 1039-1049, 1994. (Pubitemid 24292331)
15. Raingeaud J, Gupta S, Rogers JS, et al: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270: 7420-7426, 1995.
16. Ghatan S, Larner S, Kinoshita Y, et al: p38 MAP kinase mediates Bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 150: 335-347, 2000. (Pubitemid 30491357)
17. Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT and Ding J: Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther 8: 978-985, 2006.
18. Liu HF, Hu HC and Chao JI: Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact 188: 535-545, 2010.
19. Schwartz D and Rotter V: p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 8: 325-336, 1998. (Pubitemid 29131354)
20. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001. (Pubitemid 32458690)
21. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
22. Shieh SY, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997. (Pubitemid 27467963)
23. Wang Y and Prives C: Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91, 1995.
24. Gourdier I, Del Rio M, Crabbe L, et al: Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529: 232-236, 2002.
25. Toscano F, Parmentier B, Fajoui ZE, et al: p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol 74: 392-406, 2007. (Pubitemid 46963236)
26. Schwartz GK: Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23: 4499-4508, 2005.
27. Benett BK, Park SB, Lin CSY, et al: Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20: 2959-2967, 2012.
28. Gœbel FM, Tournigand C, André T, et al: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15: 1210-1214, 2004.